about
Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseasesPopulation pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemateRecommended reading in population pharmacokinetic pharmacodynamicsPKQuest: volatile solutes - application to enflurane, nitrous oxide, halothane, methoxyflurane and toluene pharmacokinetics.PKQuest: measurement of intestinal absorption and first pass metabolism - application to human ethanol pharmacokinetics.Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireviewAzithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in CatsPopulation pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats.Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adultsIn vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant Streptococcus pneumoniae populations.Systems engineering medicine: engineering the inflammation response to infectious and traumatic challenges.Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials.Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tabletsScreening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records.Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic studyPyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii.The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, UgandaPredicting the time course of haemoglobin in children treated with erythropoietin for renal anaemiaThe population pharmacokinetics of long-term methotrexate in rheumatoid arthritisPopulation pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.Population pharmacokinetics of raltitrexed in patients with advanced solid tumoursPopulation pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.Oral versus intravenous vinorelbine: clinical safety profile.Pharmacokinetic-pharmacodynamic modelling: history and perspectives.Bayesian clinical trials in actionRecent advances in pharmacokinetic modeling.Modeling the salivary cortisol profile in population research: the multi-ethnic study of atherosclerosisPharmacokinetic and pharmacodynamic data and models in clinical trials.Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.Integrated pharmacokinetics and pharmacodynamics in drug development.Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.
P2860
Q24542404-736C4A4D-4210-4E8A-95AE-E936F2F064EEQ24647717-021302DA-C77F-40D6-A0AC-FAFB86D85F8AQ24647906-A767AD43-F632-4514-9A7C-4D83BE231D53Q24799627-3E7CEA65-803B-4D16-A683-FD9A2D6AC28BQ24800505-27A984C6-44E9-4ABB-A7A7-F192559C45F2Q27025071-7C9E05F9-A7ED-4E05-8B1E-5DA489C37C0AQ30416493-B6972151-F3E2-41F1-9A25-1892AA681091Q30806067-8B591335-3530-4E9D-8EC8-CD890AC5B910Q30985350-F3F4FC65-D35F-460A-8E91-FD2CEE2B37BAQ31074386-CFC8F4FC-9FE9-4240-9810-1A7F319C15FCQ31138427-8B6BF9A9-0B96-48DC-ADCD-A79AA12FED00Q33394332-5D316C81-10EF-46E6-8E8A-128D5F7653D5Q33661085-750D7FEF-2C0C-4D2B-A28E-1C0A8264B1F9Q33692439-367F5302-AF1A-46B4-A37E-91CB4617D1E4Q33692660-9942C4A4-B5E4-4CB4-B1B1-C02E658F877DQ33747544-0F007528-8E5F-4111-8AF3-6614B99F6102Q33891519-1FCAB8F5-F762-4797-8E15-183BB151F573Q33897649-7DA02EF5-392C-48F4-A7E0-87FFF9FD009AQ33981154-6D417EAD-D96E-4F81-831C-2553DB340346Q34209542-AD1D4E5B-4078-44BE-9151-EB49BDAC8A95Q34211026-50E080F1-138A-44F9-B51D-90678D8F79AEQ34458653-9180DC74-35BA-45C1-BAE9-32DD5FE567CCQ34554435-5D6210EC-4BC4-4497-9244-3BE30EC4CDF8Q34626158-F6195406-92FB-4C92-A939-86161ADB789FQ35124802-71C55AF2-934A-4664-87F7-5979AEA418B6Q35154032-4520E78B-CFB9-4C56-AA11-F8FE60261F4BQ35802641-8BDC6D06-0D61-4791-8CE0-ACD6F7A4AE14Q35803314-1CDB8E27-93DF-4E93-9BEB-E2D27D033BC7Q35803808-B148D945-EB0D-4F4B-8B69-34AF0801B86DQ35826027-15C53AB9-B589-4360-8658-25419D558D2DQ35928858-2D27BB02-EDB8-4B2B-96A8-257DEE488955Q36235526-81D2EF9A-8E9A-4C4F-BD53-9D65E2BA74A9Q36365141-DEEAE54C-F2DA-4143-8987-BB858F2DDCF4Q36392556-3FFD2937-AAB2-4DFC-8CF8-C1659F4DAA74Q36734023-87E4F2FB-19BF-4A40-9DBF-867C5F910FFBQ36764968-14D58B24-E5D7-4C91-9145-043EDE0D7036Q36765400-E0B2AA26-6917-4D34-B06E-79B3C29E91A9Q36801536-FFDD9708-78AF-4A7E-87A7-ABACA689FCD9Q36916785-ED37C917-576E-45AA-AFB9-6C3412F4CDBEQ37363965-0D3847C9-DE4C-4F55-8723-A770BB911C37
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Population pharmacokinetics/dynamics.
@ast
Population pharmacokinetics/dynamics.
@en
type
label
Population pharmacokinetics/dynamics.
@ast
Population pharmacokinetics/dynamics.
@en
prefLabel
Population pharmacokinetics/dynamics.
@ast
Population pharmacokinetics/dynamics.
@en
P1476
Population pharmacokinetics/dynamics.
@en
P2093
P304
P356
10.1146/ANNUREV.PA.32.040192.001153
P577
1992-01-01T00:00:00Z